Actually I think its a fair price. I looked at the company a little bit ago (in the low $4's) and tried to see if one could squeeze value out of it. They have some mediocre sales, a diminishing royalty and their best potential drug failed. I wasn't overly impressed with the (relatively) new CEO too. My concern was they would just burn through their cash. I was wrong to some degree about the new CEO this was probably the best thing for shareholders.
Market Data 
Markets 
AI
